Addex creates treasury shares

Ad hoc announcement pursuant to art. 53 lr  geneva, switzerland, december 14, 2023 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the company”), announced today that 15,300,000 new registered shares at a nominal value of chf 0.01 have been issued and fully subscribed by addex pharma s.a, its 100% wholly-owned subsidiary.
ADXN Ratings Summary
ADXN Quant Ranking